Ethical Approval and Consent to participate
Both PROOF and GESPIC cohorts were approved by the local ethics committees of each study center in accordance with the local laws and regulations and is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. GESPIC was additionally approved by a central ethics committee of the coordinating center. Written informed consent to participate was obtained from all patients.
Consent for publication
Not applicable.
Availability of supporting data
The data that support the findings of this study are available from the corresponding author, N.F.G., upon reasonable request.
Competing Interests:
N.F.G, K.K.B., L.C.A., and Y.N.M. have nothing to disclose.
J.L.V reports non-financial support from Bayer, non-financial support from Guerbet, non-financial support from Medtronic, personal fees and non-financial support from Merit Medical, outside the submitted work.
S.M.N. reports grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), personal fees from Bracco Imaging, personal fees from Canon Medical Systems, personal fees from Guerbet, personal fees from Teleflex Medical GmbH, personal fees from Bayer Vital GmbH, outside the submitted work.
H.H. reports personal fees from Pfizer, personal fees from Janssen, personal fees from Novartis, personal fees from Roche, personal fees from MSD, outside the submitted work.
F.P. reports personal fees from AbbVie, personal fees from AMGEN, personal fees from BMS, personal fees from Celgene, from MSD, grants and personal fees from Novartis, personal fees from Pfizer, from Roche, personal fees from UCB, outside the submitted work.
M.R. received honoraria and/or consulting fees from AbbVie, BMS, Celgene, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB Pharma.
D.P. reports grants and personal fees from AbbVie, during the conduct of the study; grants and personal fees from AbbVie, personal fees from BMS, personal fees from Celgene, grants and personal fees from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, outside the submitted work.
V.R.R. reports personal fees from Abbvie, personal fees from Novartis, outside the submitted work.
Funding:
GESPIC was initially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF). As scheduled, BMBF was reduced in 2005 and stopped in 2007; thereafter, complementary financial support was obtained also from Abbott, Amgen, Centocor, Schering–Plough, and Wyeth. Starting in 2010, the core GESPIC cohort was supported by AbbVie. The PROOF study is funded by AbbVie. We thank AbbVie for allowing us to use the PROOF dataset for the aim of the current study.
Author’s contributions:
NFG and JLV: Data preparation, execution of model training and testing, statistical analysis, drafting and finalizing the manuscript.
KKB, YNM, DP, SMN and LCA: Essential contributions to the concept of the study, editing and correcting the manuscript.
VRR, FP, HH, and MR: Editing and correcting the manuscript.
Authors’ information
1 Charité – Universitätsmedizin Berlin, Department of Radiology, Berlin, Germany
2 Berlin Institute of Health (BIH), Berlin, Germany
3 Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology, Berlin, Germany
4 Department of Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Acknowledgements:
LCA is participant in the BIH-Charité Clinician Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of Health. KKB is participant in the BIH-Charité Digital Clinician Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of Health.